Betta Pharmaceuticals reports new KRAS degradation inducers
AI Briefing
- Betta Pharmaceuticals identifies new compounds targeting KRAS for cancer treatment.
- PROTAC compounds degrade KRAS, a potential cancer target.
- Potential therapeutic applications for the compounds are being explored.
Source Summary
Betta Pharmaceuticals Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds consisting of a Von Hippel-Lindau-binding moiety coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers. As such, they are potentially useful for the treatment of cancer.
Advertisement